OBJECTIVE: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. METHOD: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R <29; (2) YMRS <10; and (3) CGAS >50. RESULTS: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p < 0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. CONCLUSION: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.
OBJECTIVE: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. METHOD: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R <29; (2) YMRS <10; and (3) CGAS >50. RESULTS: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p < 0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. CONCLUSION:APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: R L Findling; B L Gracious; N K McNamara; E A Youngstrom; C A Demeter; L A Branicky; J R Calabrese Journal: Bipolar Disord Date: 2001-08 Impact factor: 6.744
Authors: Drew H Barzman; Melissa P DelBello; Robert A Kowatch; Beth Gernert; David E Fleck; Sanjeev Pathak; Katherine Rappaport; Sergio V Delgado; Pamela Campbell; Stephen M Strakowski Journal: J Child Adolesc Psychopharmacol Date: 2004 Impact factor: 2.576
Authors: J Wozniak; J Biederman; K Kiely; J S Ablon; S V Faraone; E Mundy; D Mennin Journal: J Am Acad Child Adolesc Psychiatry Date: 1995-07 Impact factor: 8.829
Authors: Gabrielle A Carlson; Peter S Jensen; Robert L Findling; Roger E Meyer; Joseph Calabrese; Melissa P DelBello; Graham Emslie; Laurie Flynn; Frederick Goodwin; Martha Hellander; Robert Kowatch; Vivek Kusumakar; Thomas Laughren; Ellen Leibenluft; James McCracken; Editha Nottelmann; Daniel Pine; Gary Sachs; David Shaffer; Renee Simar; Michael Strober; Elizabeth B Weller; Janet Wozniak; Eric A Youngstrom Journal: J Child Adolesc Psychopharmacol Date: 2003 Impact factor: 2.576
Authors: José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui Journal: Eur Child Adolesc Psychiatry Date: 2013-03-17 Impact factor: 4.785